343 related articles for article (PubMed ID: 30711575)
21. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development.
Mubarak A; Alturaiki W; Hemida MG
J Immunol Res; 2019; 2019():6491738. PubMed ID: 31089478
[TBL] [Abstract][Full Text] [Related]
22. Influenza chemotherapy: a review of the present state of art and of new drugs in development.
Lüscher-Mattli M
Arch Virol; 2000; 145(11):2233-48. PubMed ID: 11205114
[TBL] [Abstract][Full Text] [Related]
23. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections.
Bauer L; Lyoo H; van der Schaar HM; Strating JR; van Kuppeveld FJ
Curr Opin Virol; 2017 Jun; 24():1-8. PubMed ID: 28411509
[TBL] [Abstract][Full Text] [Related]
24. Recent discoveries of influenza A drug target sites to combat virus replication.
Patel H; Kukol A
Biochem Soc Trans; 2016 Jun; 44(3):932-6. PubMed ID: 27284062
[TBL] [Abstract][Full Text] [Related]
25. Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication.
Perwitasari O; Yan X; O'Donnell J; Johnson S; Tripp RA
Assay Drug Dev Technol; 2015 Dec; 13(10):638-49. PubMed ID: 26192013
[TBL] [Abstract][Full Text] [Related]
26. Modulation of Innate Immune Responses by the Influenza A NS1 and PA-X Proteins.
Nogales A; Martinez-Sobrido L; Topham DJ; DeDiego ML
Viruses; 2018 Dec; 10(12):. PubMed ID: 30545063
[TBL] [Abstract][Full Text] [Related]
27. Natural Products as Promising Therapeutics for Treatment of Influenza Disease.
Sencanski M; Radosevic D; Perovic V; Gemovic B; Stanojevic M; Veljkovic N; Glisic S
Curr Pharm Des; 2015; 21(38):5573-88. PubMed ID: 26429712
[TBL] [Abstract][Full Text] [Related]
28. Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs.
Schor S; Einav S
DNA Cell Biol; 2018 Feb; 37(2):63-69. PubMed ID: 29148875
[TBL] [Abstract][Full Text] [Related]
29. A molecular arms race between host innate antiviral response and emerging human coronaviruses.
Wong LY; Lui PY; Jin DY
Virol Sin; 2016 Feb; 31(1):12-23. PubMed ID: 26786772
[TBL] [Abstract][Full Text] [Related]
30. Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains.
Shin WJ; Seong BL
Expert Opin Drug Discov; 2019 Feb; 14(2):153-168. PubMed ID: 30585088
[TBL] [Abstract][Full Text] [Related]
31. Current advances in anti-influenza therapy.
Saladino R; Barontini M; Crucianelli M; Nencioni L; Sgarbanti R; Palamara AT
Curr Med Chem; 2010; 17(20):2101-40. PubMed ID: 20423307
[TBL] [Abstract][Full Text] [Related]
32. Drug repurposing of quinine as antiviral against dengue virus infection.
Malakar S; Sreelatha L; Dechtawewat T; Noisakran S; Yenchitsomanus PT; Chu JJH; Limjindaporn T
Virus Res; 2018 Aug; 255():171-178. PubMed ID: 30055216
[TBL] [Abstract][Full Text] [Related]
33. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses.
Wong JP; Christopher ME; Viswanathan S; Dai X; Salazar AM; Sun LQ; Wang M
Curr Pharm Des; 2009; 15(11):1269-74. PubMed ID: 19355966
[TBL] [Abstract][Full Text] [Related]
34. Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Mercorelli B; Palù G; Loregian A
Trends Microbiol; 2018 Oct; 26(10):865-876. PubMed ID: 29759926
[TBL] [Abstract][Full Text] [Related]
35. A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.
Nicholson EG; Munoz FM
Clin Ther; 2018 Aug; 40(8):1268-1281. PubMed ID: 30077340
[TBL] [Abstract][Full Text] [Related]
36. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.
Kim Y; Liu H; Galasiti Kankanamalage AC; Weerasekara S; Hua DH; Groutas WC; Chang KO; Pedersen NC
PLoS Pathog; 2016 Mar; 12(3):e1005531. PubMed ID: 27027316
[TBL] [Abstract][Full Text] [Related]
37. Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update.
Han Y; Mesplède T
Expert Opin Investig Drugs; 2018 Dec; 27(12):951-962. PubMed ID: 30430882
[TBL] [Abstract][Full Text] [Related]
38. New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections.
van de Wakker SI; Fischer MJE; Oosting RS
Eur J Pharmacol; 2017 Aug; 809():178-190. PubMed ID: 28533172
[TBL] [Abstract][Full Text] [Related]
39. Gene expression signatures as a therapeutic target for severe H7N9 influenza - what do we know so far?
Morrison J; Katze MG
Expert Opin Ther Targets; 2015 Apr; 19(4):447-50. PubMed ID: 25600759
[TBL] [Abstract][Full Text] [Related]
40. Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery.
de Chassey B; Meyniel-Schicklin L; Aublin-Gex A; André P; Lotteau V
Mol Biosyst; 2012 Apr; 8(4):1297-303. PubMed ID: 22307679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
